Aecon Group Inc. (TSX:ARE)
Canada · Delayed Price · Currency is CAD 20.76
+0.01 (0.05%)
Aug 13, 2025, 4:00 PM EDT
Achilles Therapeutics Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Revenue | 4,906 | 4,243 | 4,644 | 4,696 | 3,977 | 3,644 | Upgrade |
Revenue Growth (YoY) | 20.53% | -8.64% | -1.12% | 18.08% | 9.16% | 5.29% | Upgrade |
Cost of Revenue | 4,529 | 4,060 | 4,388 | 4,340 | 3,649 | 3,332 | Upgrade |
Gross Profit | 376.37 | 182.55 | 255.63 | 355.96 | 328.12 | 311.85 | Upgrade |
Selling, General & Admin | 229.33 | 213.25 | 177.84 | 196.44 | 175.48 | 172.72 | Upgrade |
Other Operating Expenses | -0.36 | - | - | -4.43 | -2.67 | -5.15 | Upgrade |
Operating Expenses | 329.94 | 301.1 | 256.93 | 286.16 | 261.18 | 259.26 | Upgrade |
Operating Income | 46.43 | -118.55 | -1.3 | 69.8 | 66.94 | 52.59 | Upgrade |
Interest Expense | -54.78 | -44.68 | -60.66 | -57.07 | -45.63 | -26.94 | Upgrade |
Interest & Investment Income | 6.37 | 8.64 | 7.67 | 2.9 | 0.61 | 1.05 | Upgrade |
Earnings From Equity Investments | 11.02 | 21.21 | 18.75 | 17.7 | 15.1 | 14.08 | Upgrade |
Currency Exchange Gain (Loss) | 3.54 | 2.55 | 0.16 | 1.52 | -0.78 | -0.18 | Upgrade |
Other Non Operating Income (Expenses) | 17.17 | 19.57 | -10.38 | - | - | - | Upgrade |
EBT Excluding Unusual Items | 29.75 | -111.26 | -45.76 | 34.85 | 36.24 | 40.6 | Upgrade |
Gain (Loss) on Sale of Investments | 0.79 | 0.79 | 0.94 | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | 10.25 | 33.95 | 222.36 | 8.14 | 5.65 | 3.66 | Upgrade |
Other Unusual Items | - | - | - | - | 31.9 | 79.7 | Upgrade |
Pretax Income | 40.79 | -76.53 | 177.55 | 42.99 | 73.79 | 123.97 | Upgrade |
Income Tax Expense | 16.16 | -17.09 | 15.66 | 12.61 | 24.11 | 35.94 | Upgrade |
Earnings From Continuing Operations | 24.62 | -59.44 | 161.89 | 30.38 | 49.68 | 88.03 | Upgrade |
Minority Interest in Earnings | 0.31 | -0.08 | - | - | - | - | Upgrade |
Net Income | 24.93 | -59.52 | 161.89 | 30.38 | 49.68 | 88.03 | Upgrade |
Net Income to Common | 24.93 | -59.52 | 161.89 | 30.38 | 49.68 | 88.03 | Upgrade |
Net Income Growth | 90.18% | - | 432.87% | -38.85% | -43.56% | 20.83% | Upgrade |
Shares Outstanding (Basic) | 63 | 62 | 62 | 61 | 60 | 60 | Upgrade |
Shares Outstanding (Diluted) | 63 | 62 | 82 | 65 | 74 | 76 | Upgrade |
Shares Change (YoY) | -13.02% | -23.86% | 26.75% | -12.47% | -2.67% | 2.74% | Upgrade |
EPS (Basic) | 0.40 | -0.95 | 2.62 | 0.50 | 0.82 | 1.47 | Upgrade |
EPS (Diluted) | 0.40 | -0.95 | 2.10 | 0.47 | 0.81 | 1.29 | Upgrade |
EPS Growth | 88.27% | - | 347.76% | -42.16% | -37.26% | 15.25% | Upgrade |
Free Cash Flow | -88.51 | -44.13 | 32.56 | -146.37 | -66.79 | 235.22 | Upgrade |
Free Cash Flow Per Share | -1.41 | -0.71 | 0.40 | -2.26 | -0.90 | 3.10 | Upgrade |
Dividend Per Share | 0.760 | 0.760 | 0.740 | 0.740 | 0.700 | 0.640 | Upgrade |
Dividend Growth | 1.33% | 2.70% | - | 5.71% | 9.38% | 10.35% | Upgrade |
Gross Margin | 7.67% | 4.30% | 5.50% | 7.58% | 8.25% | 8.56% | Upgrade |
Operating Margin | 0.95% | -2.79% | -0.03% | 1.49% | 1.68% | 1.44% | Upgrade |
Profit Margin | 0.51% | -1.40% | 3.49% | 0.65% | 1.25% | 2.42% | Upgrade |
Free Cash Flow Margin | -1.80% | -1.04% | 0.70% | -3.12% | -1.68% | 6.46% | Upgrade |
EBITDA | 95.31 | -65.06 | 48.4 | 129.04 | 122.05 | 107.27 | Upgrade |
EBITDA Margin | 1.94% | -1.53% | 1.04% | 2.75% | 3.07% | 2.94% | Upgrade |
D&A For EBITDA | 48.88 | 53.49 | 49.7 | 59.24 | 55.11 | 54.68 | Upgrade |
EBIT | 46.43 | -118.55 | -1.3 | 69.8 | 66.94 | 52.59 | Upgrade |
EBIT Margin | 0.95% | -2.79% | -0.03% | 1.49% | 1.68% | 1.44% | Upgrade |
Effective Tax Rate | 39.63% | - | 8.82% | 29.33% | 32.67% | 28.99% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.